SpringerProtocols: Abstract: Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases

Heparin and Low Molecular Weight Heparin in Thrombosis, Cancer, and Inflammatory Diseases

By: Shaker A. Mousa²

Abstract

Full Text

Download PDF (133K)

Despite the research and development efforts in newer anticoagulants, unfractionated heparin (UFH) and low molecular weight heparin (LMWH) will continue to play a pivotal role in the management of thrombotic disorders. Although bleeding and heparin-induced thrombocytopenia (HIT) represent major side effects of this drug, it has remained the anticoagulant of choice for the prophylaxis and treatment of arterial and venous thrombotic disorders, surgical anticoagulation, and interventional usage. It is the understanding of the structure of heparin that led to the development of LMWHs, synthetic hepari-nomimetics, antithrombin (AT), and anti-Xa agents.

Affiliation(s): (2) Albany College of Pharmacy, Albany, NY

Book Title: Anticoagulants, Antiplatelets, and Thrombolytics

Series: Methods in Molecular Medicine | Volume: 93 | Pub. Date: Nov-03-2003 | Page Range: 35-48 | DOI: 10.1385/1-59259-658-4:35

Subject: Molecular Medicine

References

Download References

1.	Weitz, J. I. (1997) Low-molecular-weight heparin. N. Engl. J. Med. 337, 688–698.

2.	Mousa, S. A. and Fareed, J. W. (2001) Advances in anticoagulant, antithrombotic and thrombolytic drugs. Exp. Opin. Invest. Drugs 10(1), 157–162.

3.	Fegan, C. D. (1998) Tinzaparin as an antithrombotic: an overview. Hosp. Med. 149, 1285–1288.

4.	Aguilar, D. and Goldhaber, S. Z. (1999) Clinical uses of low molecular weight heparin. Chest 115(5), 1418–1423.

5.	Linhardt, R. J. and Gunay, N. S. (1999) Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 25(3), 5–16.

6.	Mousa, S. A. (2000) Comparative efficacy among different low molecular weight heparin (LMWHs) & drug interaction: implications in the management of vascular disorders. Thromb. Haemostasis 26(l)(Suppl. 1), 39–46. This study provides a comparative total anticoagulant efficacy among different LMWH showing dependency on the molecular weight and degree of sulfation.

7.	Hull, R. D., Raskob, G. E., Pineo, G. F., Green, D., Towbridge, A. A., Elliott, C. G, et al. (1992) Subcutaneous low-molecular weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N. Engl. J. Med. 326, 975–982. This is a key double-blind clinical trial comparing the efficacy and safety of LMWH to UFH in-patients with VTE.

8.	Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.-P., Bosson, J.-L., et al. (1997) A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N. Engl. J. Med. 337, 663–669.

9.	Hull, R. D., Raskob, G E., Pineo, G F., Rosenbloom, D., Evans, W., Mallory, T., et al. (1993) A comparison of subcutaneous low-molecular weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N. Engl. J. Med. 329, 1370–1376.

10.	Leizorovicz, A., Picolet, H., Peyrieux, J. C, Boissel, J. P., and the HBPM research group. (1991) Prevention of perioperative deep vein thrombosis in general surgery: a multicenter double blind study comparing two doses of logiparin and standard heparin. Br. J. Surg. 78, 412–416.

11.	Ryan, K. E., Lane, D. A., Flynn, A., Shepperd, J., Ireland, H. A., and Curtis, J. R. (1991) Dose finding study of a low molecular weight heparin, tinzaparin, in haemodialysis. Thromb. Haemostasis 66(3), 277–282.

12.	Pedersen, P. C, Østergaard, P. B., Hedner, U., Bergqvist, D., and Mätzsch, T. (1991) Pharmacokinetics of low molecular weight heparin, logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb. Res. 61, 477–487.

13.	Mätzsch, T., Bergqvist, D., Hedner, U., and Østergaard, P. B. (1987) Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers. Thromb. Haemostasis 57(1), 97–101.

14.	Mousa, S. A., Bozarth, J., Hainer, J., et al. (2001) Pharmacodynamic of tinzaparin following 175 IU/Kg SC administration in healthy volunteers on plasma TFPI. Thromb. Haemostasis P2299.

15.	Emmanuele, R. M. and Fareed, J. (1987) The effect of molecular weight on the bioavailability of heparin. Thromb. Res. 48, 591–596.

16.	Brieger, D. and Dawes, J. (1997) Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb. Haemostasis 77(2), 317–322.

17.	Mousa, S. A., Bozarth, J., Larnkjaer, A., and Johanson, K. (2000) Vascular effects of heparin molecular weight fractions and LMWH on the release of TFPI from human endothelial cells. Blood 16(11), 59, 3928.

18.	Kaiser, B., Hoppensteadt, D., and Fareed, J. (2000) Tissue factor pathway inhibitor for cardiovascular disorders. Emerging Drugs 5(1), 73–87.

19.	Verstraete, M. (1990) Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. Drugs 40, 498–530.

20.	Lindblad, B. (1988) Prophylaxis of postoperative thromboembolism with low dose heparin alone or in combination with dihydroergotamine. A review. Acta Chir. Scand. Suppl. 543, 31–42.

21.	Hull, R., Delmore, T, Carter, C, Hirsh, J., Genton, E., Gent, M., et al. (1982) Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl. J. Med. 306, 189–194.

22.	Hull, R. D., Raskob, G E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., et al. (1986) Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N. Engl. J. Med. 315, 1109–1114.

23.	Cruickshank, M. K., Levine, M. N., Hirsh, J., Roberts, R., and Siguenza, M. (1991) A standard heparin nomogram for the management of heparin therapy [see comments]. Arch. Intern. Med. 151, 333–337.

24.	Hull, R. D., Raskob, G. E., Rosenbloom, D., Lemaire, J., Pineo, G. F, Baylis, B., et al. (1992) Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch. Intern. Med. 152, 1589–1595.

25.	Goldhaber, S. Z. (1996) Thrombolytic therapy for venous thromboembolism, in Disorders of Thrombosis (Hull, R. and Pineo, G. F., eds.), W.B. Saunders Co, pp. 321–328.

26.	Gueret, P., Dubourg, O., Ferrier, A., Farcot, J. C, Rigaud, M., and Bourdarias, J. P. (1986) Effects of full-dose heparin anticoagulation on the development of left ventricular thrombosis in acute transmural myocardial infarction. J. Am. Coll. Cardiol. 8, 419–426.

27.	Neri Serneri, G. G, Gensini, G. F, Poggesi, L., Trotta, F, Modesti, P. A., Boddi, M., et al. (1990) Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina (published erratum appears in Lancet 1990 Apr 7;335[8693]:868). Lancet 335, 615–618.

28.	Bounameaux, H., Verhaeghe, R., and Verstraete, M. (1986) Thromboembolism and antithrombotic therapy in peripheral arterial disease. J. Am. Coll. Cardiol. 8, 98B–103B.

29.	Matzsch, T., Bergqvist, D., Hedner, U., Nilsson, B., and Ostergaard, P. (1986) Heparin-induced osteoporosis in rats. Thromb. Haemostasis 56, 293–294.

30.	Salzman, E. W., Rosenberg, R. D., Smith, M. H., Lindon, J. N., and Favreau, L. (1980) Effect of heparin and heparin fractions on platelet aggregation. J. Clin. Invest. 65, 64–73.

31.	Friedel, H. A. and Balfour, J. A. (1994) Tinzaparin. A review of its pharmacology and clinical potential in the prevention and treatment of thromboembolic disorders. Drugs 48, 638–660.

32.	Padilla, A., Gray, E., Pepper, D. S., and Barrowcliffe, T. W. (1992) Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4). Br. J. Haematol. 82, 406–413.

33.	Fareed, J., Jeske, W., Hoppensteadt, D., Clarizio, R., and Walenga, J. M. (1998) Low-molecular-weight heparins: pharmacological profile and product differentiation. Am. J. Cardiol. 82, 3L–10L.

34.	Boneu, B., Caranobe, C, Cadroy, Y., Dol, F., Gabaig, A. M., Dupouy, D., et al. (1988) Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin. Thromb. Hemost. 14, 18–27.

35.	Sutor, A. H., Massicotte, P., Leaker, M., Andrew, M. (1997) Heparin therapy in pediatric patients. Semin. Thromb. Hemost. 23, 303–319.

36.	Fareedman, M. D. (1996) Low molecular weight heparins: an emerging new class of glycosaminoglycan antithrombotic. J. Clin. Pharmacol. 31, 298–306. Circulation 93, 2212–2245.

37.	Fareed, J., Walenga, J. M., Hoppensteadt, D., Huan, X., and Nonn, R. (1989) Biochemical and pharmacological in-equivalence of low molecular weight heparins. Ann. NY Acad. Sci. 556, 333–353.

38.	Lindahl, A. K., Abildgaard, U., and Stokke, G. (1990) Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Thromb. Res. 59, 651–656.

39.	Larnkjaer, A., Ostergaard, P. B., and Flodgaard, H. J. (1994) Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro. Thromb. Res. 75, 185–194.

40.	Ostergaard, P., Nordfang, O., Petersen, L. C., Valentin, S., and Kristensen, H. (1993) Is tissue factor pathway inhibitor involved in the antithrombotic effect of heparins? Biochemical considerations. Haemostasis 23 (Suppl. 1), 107–111.

41.	Hull, R. D., Raskob, G E., Rosenbloom, D., Pineo, G., Lerner, R. G, Gafni, A., et al. (1997) Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs. intravenous heparin. Arch. Intern. Med. 157, 289–294.

Comments (Loading...)

Post comment/View all comments